A Study of RO5310074 in Patients With Psoriatic Arthritis
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind. placebo-controlled study will assess the safety, tolerability,
pharmacokinetics and pharmacodynamics of multiple doses of RO5310074 in patients with
psoriatic arthritis who have or have had an inadequate response to oral disease-modifying
antirheumatic drugs (DMARDs) or non-steroidal anti-rheumatic drugs (NSAIDs). Patients will be
randomized in cohorts to receive either 6 intravenous doses of RO5310074 or placebo.
Anticipated time on study treatment is 12 weeks.